A Phase 1/2 Multicenter Dose Escalation and Expansion Study Of NKTR-214 In Subjects With Locally Advanced Or Metastatic Solid Tumors - Trial NCT02869295
Access comprehensive clinical trial information for NCT02869295 through Pure Global AI's free database. This Early Phase 1 trial is sponsored by Nektar Therapeutics and is currently Completed. The study focuses on Unspecified Adult Solid Tumor, Protocol Specific. Target enrollment is 28 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Nektar Therapeutics
Timeline & Enrollment
Early Phase 1
Dec 01, 2015
Oct 31, 2018
Primary Outcome
Safety of NKTR-214 as Evaluated by Incidence of Drug-related Adverse Events (AEs),Tolerability of NKTR-214 as Evaluated by Incidence of Dose Limiting Toxicities (DLTs)
Summary
This is a first in human, open-label, sequential dose escalation and expansion Phase 1 study
 of NKTR-214 in adult patients with locally advanced or metastatic solid tumors.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT02869295
Non-Device Trial